Celltrion, Inc. reported second-quarter revenue of ₩1,393.7bn, up 45% year on year, and operating income of ₩451.8bn, a 32.4% margin, both records for a second quarter.
Celltrion's cost of revenue fell 9.6% in FY2025 while revenue grew 17.0%, an outcome no volume or pricing story can produce on its own.
Celltrion's retained earnings fell about ₩1.3tn in the second quarter of 2026 despite ₩371.3bn of profit, which points to roughly ₩1.5tn of share cancellation.
Celltrion terminated the European arm of its Keytruda biosimilar Phase 3 on 14 July 2026 and withdrew the trial plan, citing a changed global regulatory environment.
Celltrion (KRX:068270) posted first-half 2026 revenue growth of 18% year-over-year despite a 15% decline in consolidated revenue, as contract manufacturing volumes from third-party clients offset a cyclical slowdown in its own biosimilar product sales.
Celltrion (KRX:068270) biosimilar Stekla, a copy of Janssen's ustekinumab for autoimmune disease, held 16.2% of the US market by volume in July 2026, up from 14.9% in June, data-tracking firm IQVIA reported Wednesday.
Celltrion's biosimilar Stekima has captured 16.2% market share in the US ustekinumab category as of July 2026.
Celltrion (068270) said in a regulatory filing Monday that its board approved buying back up to 524,384 common shares, worth as much as ₩100.0bn (~$72.6m), with purchases running from September 1 through November 30.
| Period | 068270 | KOSPI | Difference |
|---|---|---|---|
| 1 week | -1.4% | -1.5% | +0.1% |
| 1 month | +1.2% | +5.2% | -3.9% |
| 3 months | +6.6% | -22.6% | +29.2% |
| 6 months | -0.0% | +31.3% | -31.3% |
| Year to date | +9.0% | +58.7% | -49.7% |
| 1 year | +15.9% | +108.9% | -93.0% |
Closed at 37% of the way from its 52-week low (₩159,400) to its 52-week high (₩236,861).
Celltrion's board approved buying 524,384 of its own shares on the open market between September 1 and November 30, an estimated ₩100.0bn based on the ₩190,700 close the day before the resolution. That is 0.23% of the 232.6m shares outstanding and about 0.2% of a ₩43.7tn market capitalisation, but close to 10% of FY2025 net income of ₩1.03tn. The company states it plans to cancel the entire amount, which is the part worth noting, because Korean companies frequently buy without ever cancelling. It has already retired 9,598,977 shares so far in 2026, leaving 3,983,455 in treasury. The cost is not fixed: ₩100.0bn is a price-based estimate and the actual spend moves with the market. NH Investment & Securities is the executing broker, and the filing shows ₩4.46tn of headroom under the distributable-profit limit.
Celltrion is South Korea's largest biosimilar company. Biosimilars are near-copies of biologic drugs — the complex, protein-based medicines like Humira, Remicade and Stelara that cannot be duplicated as exactly as a chemical pill can. Celltrion built the first biosimilar of Remicade to win approval in Europe and the United States, and has since built a portfolio spanning autoimmune, oncology and metabolic drugs, sold under names such as Yuflyma, Zymfentra and Steqeyma. Its main competitors are Sandoz, Amgen, Samsung Bioepis and Pfizer's biosimilar unit. In 2023 the company absorbed its former marketing affiliate, Celltrion Healthcare, ending a long-criticized structure in which the manufacturer sold to a related distributor. For a US reader, think of it as a manufacturer competing on price and speed against branded biologics whose patents are expiring, with the US market as its largest single opportunity.
| Sector | Biopharma | Employees | |
| Market | KOSPI | Founded | |
| Korean name | 셀트리온 | Head office |
| Symbol | Last Price |
|---|---|
| 207940Samsung Biologics Co., Ltd. | ₩1,447,000 -2.0% |
| 196170Alteogen Inc. | ₩288,500 +1.9% |
| 326030SK biopharmaceuticals Co., Ltd. | ₩86,600 +0.2% |
| 128940Hanmi Pharm. Co., Ltd. | ₩473,500 +2.8% |
| 000100Yuhan Corporation | ₩81,400 +0.0% |
| 028300HLB Co., Ltd. | ₩33,750 +2.9% |
| 298380ABL Bio Inc. | ₩71,400 +5.6% |
| 000250Samchundang Pharm | ₩157,000 +1.0% |
| 087010Peptron, Inc. | ₩157,300 +7.3% |
| 141080LigaChem Biosciences Inc. | ₩92,000 +4.2% |